At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 100 enrolled
Drug / intervention
Atorvastatindrug
Likely dose
Atorvastatin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome
National Institute of Kidney Disease and Urology (NIKDU)·interventional·Posted Mar 27, 2026·Updated Mar 27, 2026
In Brief
A Phase 4 clinical trial evaluating Atorvastatin for Dyslipidaemia. Completed, enrolled 100 participants across 1 site.
Detailed Summary
To evaluate the effectiveness and safety of Atorvastatin therapy in children with dyslipidemia in steroid sensitive nephrotic syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidaemia
CountriesBangladesh
Collaborators--
Timeline
Phase 4CompletedFinished
202420252026
Enrollment StartJan 2024
Primary CompletionAug 2025
Study CompletionOct 2025
First PostedMar 2026
TodayJul 2026
First PostedMar 27, 2026
Enrollment StartJan 27, 2024
Primary CompletionAug 30, 2025
Study CompletionOct 31, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3 months ago
Interventions
Atorvastatindrug
Atorvastatin 10 mg nightly dose